Furthermore, poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are also known to elicit a good response in pancreatic cancer patients with DDR gene mutations, so future studies are needed to determine whether ERCC6 mutations play a role in the response to PARP inhibitors [36]. The gene discussed is ERCC6; the disease is familial pancreatic carcinoma.